Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Rhea-AI Summary

Oculis (OCS) announced a notification related to transactions by a person discharging managerial responsibilities. The attached document concerns the vesting and settlement of RSUs previously granted to a company director, identified as Arshad Khanani, with a vesting date of May 25, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

News Market Reaction – OCS

-23.42% 2.6x vol

41 alerts

-23.42% News Effect

-64.0% Trough in 2 hr 15 min

-$513M Valuation Impact

$1.68B Market Cap

2.6x Rel. Volume

On the day this news was published, OCS declined 23.42%, reflecting a significant negative market reaction. Argus tracked a trough of -64.0% from its starting point during tracking. Our momentum scanner triggered 41 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $513M from the company's valuation, bringing the market cap to $1.68B at that time. Trading volume was elevated at 2.6x the daily average, suggesting increased selling activity.

Data tracked by StockTitan Argus on the day of publication.

What This Means

The stock dropped -23.4% in the session following this news. A negative reaction despite a routine R...

Analysis

The stock dropped -23.4% in the session following this news. A negative reaction despite a routine RSU vesting disclosure would fit a pattern where Oculis has occasionally sold off after otherwise constructive updates, such as prior clinical or financial news. With shares already below the 52-week high but above the 200-day MA, traders may use non-fundamental headlines as liquidity points. The filing itself simply documents compensation-related mechanics for a director, against an already active backdrop of trials and prior financings.

Key Figures

RSU vesting date: May 25, 2026 Announcement date: May 28, 2026

2 metrics

RSU vesting date May 25, 2026 Vesting and settlement of RSUs for a company director

Announcement date May 28, 2026 Publication date of PDMR transaction notification

Historical Context

5 past events · Latest: May 15 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 15	PDMR transactions notice	Neutral	-7.3%	Disclosure of RSU vesting, incentive awards, and new director equity grant.
May 14	AGM results & capital	Neutral	+0.2%	All AGM items approved, loss disclosure, and capital band/conditional capital authorizations.
May 11	Q1 results & pipeline	Positive	-6.9%	Q1 2026 results, strong cash runway, and multiple key trial timelines outlined.
May 07	SPA for Phase 3	Positive	+5.1%	FDA Special Protocol Assessment for PIONEER-1 optic neuritis registrational trial.
May 05	DME study update	Positive	-1.8%	DME AWARE Delphi findings and reminder of upcoming DIAMOND Phase 3 topline data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often involved clinical and financing milestones; positive clinical or financing updates have sometimes seen negative next-day moves, indicating occasional divergence between news tone and price.

Recent Company History

Over the past month, OCS has reported several developments, from SPA agreement for Privosegtor and DME AWARE study data to Q1 2026 results and AGM outcomes. These events included advancing Phase 3 trials, securing regulatory alignment, and disclosing losses and capital structure changes. A prior managers’ transactions notice on May 15, 2026 coincided with a -7.33% move. Today’s RSU vesting notification fits this pattern of governance and compensation transparency alongside an already active clinical and financing backdrop.

Regulatory & Risk Context

Active S-3 Shelf · $6,877,246.59 · Short Interest: 1.22%

Shelf Active

Short Interest

1.22% of shares outstanding

as of 2026-05-29 Days to cover: 1

Active S-3 Shelf Registration 2025-11-10

$6,877,246.59 registered capacity

An effective Form F-3 dated November 10, 2025 registers resale of up to 494,259 warrant-linked ordinary shares by a selling securityholder. Oculis is not selling shares under this prospectus and would only receive up to $6,877,246.59 if the warrant is fully exercised for cash; resale proceeds go to the holder, not the company.

Key Terms

persons discharging managerial responsibilities, rsus

2 terms

persons discharging managerial responsibilities regulatory

"Notifications of Transactions by Persons Discharging Managerial Responsibilities"

Persons Discharging Managerial Responsibilities are the key people in a company who make big decisions, like top managers or executives. Knowing who they are is important because their actions can influence the company’s success or failure, and they are often required to share information about their dealings to ensure transparency for investors and the public.

rsus financial

"relates to the vesting and settlement of RSUs previously granted"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZUG, Switzerland, May 28, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.

Attachment

• Notification of managers' transaction - Arshad Khanani - 25 May 2026 RSU vest

FAQ

What transaction by management did Oculis (OCS) disclose on May 28, 2026?

Oculis disclosed a notification relating to the vesting and settlement of RSUs previously granted to a company director. According to Oculis, the attached document details this managers' transaction involving a person discharging managerial responsibilities.

Who is involved in the Oculis (OCS) managers' transaction notification published on May 28, 2026?

The notification concerns company director Arshad Khanani. According to Oculis, the attached managers' transaction document relates specifically to the vesting and settlement of RSUs associated with Khanani, dated May 25, 2026.

What type of equity award is referenced in the latest Oculis (OCS) managers' transaction filing?

The filing references the vesting and settlement of RSUs. According to Oculis, these RSUs were previously granted to a director, with details of the managers' transaction provided in the attached notification dated May 25, 2026.

What is the transaction date mentioned in the Oculis (OCS) RSU vesting notification?

The transaction date mentioned is May 25, 2026. According to Oculis, the attached notification describes the vesting and settlement of RSUs for a director as a managers' transaction occurring on that date.

Why did Oculis (OCS) publish a notification about RSU vesting for a director?

Oculis published the notification to report a managers' transaction involving RSU vesting and settlement. According to Oculis, the attached document covers RSUs previously granted to director Arshad Khanani that vested on May 25, 2026.